Jason Gerberry
Stock Analyst at B of A Securities
(3.65)
# 825
Out of 4,996 analysts
162
Total ratings
56.9%
Success rate
4.41%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $81 → $83 | $64.09 | +29.51% | 6 | Sep 23, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $26.84 | +19.23% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $16.23 | +84.84% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $15.00 | +226.67% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $116.76 | +50.74% | 6 | Aug 5, 2025 | |
| PROK ProKidney | Downgrades: Underperform | $3 → $1 | $2.49 | -59.84% | 4 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $21.80 | +5.50% | 2 | Jun 11, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $45 → $46 | $39.04 | +17.83% | 3 | Jun 5, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $18.34 | +19.96% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $33.98 | +303.18% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $9.52 | +5.04% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $19.52 | +53.69% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $79.69 | +25.49% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $5.17 | +364.22% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $17.68 | +13.15% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $33.78 | -8.23% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $6.47 | +8,400.77% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $27.89 | +3.98% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $32.80 | +12.80% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $37.98 | +47.45% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $27.51 | +9.05% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $127.00 | +70.87% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $12.31 | +306.17% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $724.54 | -30.99% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.25 | +620.00% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $10.21 | +144.86% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.76 | +184.09% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $6.48 | +316.67% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.50 | +1,233.33% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $4.18 | +2,292.34% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $220.61 | -56.94% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $44.12 | +35.99% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $23.76 | +55.72% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $78.56 | +14.56% | 11 | Oct 17, 2019 |
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $81 → $83
Current: $64.09
Upside: +29.51%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $26.84
Upside: +19.23%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $16.23
Upside: +84.84%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $15.00
Upside: +226.67%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $116.76
Upside: +50.74%
ProKidney
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.49
Upside: -59.84%
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $21.80
Upside: +5.50%
Exelixis
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $39.04
Upside: +17.83%
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $18.34
Upside: +19.96%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $33.98
Upside: +303.18%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $9.52
Upside: +5.04%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $19.52
Upside: +53.69%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $79.69
Upside: +25.49%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $5.17
Upside: +364.22%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $17.68
Upside: +13.15%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $33.78
Upside: -8.23%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $6.47
Upside: +8,400.77%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $27.89
Upside: +3.98%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $32.80
Upside: +12.80%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $37.98
Upside: +47.45%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $27.51
Upside: +9.05%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $127.00
Upside: +70.87%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $12.31
Upside: +306.17%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $724.54
Upside: -30.99%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.25
Upside: +620.00%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $10.21
Upside: +144.86%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.76
Upside: +184.09%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $6.48
Upside: +316.67%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.50
Upside: +1,233.33%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $4.18
Upside: +2,292.34%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $220.61
Upside: -56.94%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $44.12
Upside: +35.99%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $23.76
Upside: +55.72%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $78.56
Upside: +14.56%